THOMAS S. MCHUGH - 07 Dec 2021 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Chief Financial Officer
Signature
/s/ Jerad Seurer, as Attorney-in-Fact
Issuer symbol
AVDL
Transactions as of
07 Dec 2021
Net transactions value
$0
Form type
4
Filing time
09 Dec 2021, 17:44:27 UTC
Next filing
31 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 07 Dec 2021 ADSs 150,000 $8.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options become exercisable as to 37,500 ADSs on each of the first four anniversaries after the 12/07/2021 grant date.
F2 The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.